Trials show unique stem cells a potential asthma treatment

June 28, 2017, Monash University
Trials show unique stem cells a potential asthma treatment
Lead researchers Dr Simon Royce and Associate Professor Chrishan Samuel. Credit: Monash University

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

The Monash Biomedicine Discovery Institute (BDI) scientists provided the experimental expertise to test Cynata Therapeutics' induced -derived mesenchymal (MSCs) in a model of experimental asthma. Induced pluripotent stem cells are a type of pluripotent stem cell that can be generated directly from adult cells; they have the ability to be differentiated into a variety of tissue types and, in this case, MSCs that can regenerate damaged lung tissue.

Lead researchers Associate Professor Chrishan Samuel and Dr Simon Royce tested the efficacy of the MSCs on three key components of asthma in a preclinical model of chronic allergic airways disease: inflammation; airway remodeling (structural changes that occur in lungs as a result of prolonged inflammation); and airway hyperresponsiveness (the clinical symptom of asthma).

The study, published in the FASEB Journal, found that the MSCs could effectively reduce inflammation, reversed signs of airway remodelling and completely normalised airway/lung fibrosis and hyperresponsiveness, particularly when delivered intranasally.

It concluded that they may provide a novel stand-alone therapy or an adjunct therapy for groups of asthma sufferers who do not respond to current (corticosteroid) therapy.

"Most importantly, what we found was you can treat fibrosis (hardening or scarring of the lung) very effectively," said Associate Professor Samuel, who heads the Monash BDI's Fibrosis Laboratory.

"When we've tested other types of stem cells they haven't been able to fully reverse scarring and lung dysfunction associated with asthma – we've had to combine them with anti-scarring drugs to achieve that. These cells were remarkable on their own as they were able to effectively reverse the scarring that contributes to lung dysfunction and difficulty in breathing," he said.

One in nine—or around 2.5 million—Australians have asthma.

Further research will be conducted to test the MSCs in combination with, or compared to a clinically-used corticosteroid. Clinical trials using the as a novel target for are then envisaged.

Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus stem cell technology platform.

Explore further: MicroRNAs identified as novel targets for treating asthma

More information: Simon G. Royce et al. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease, The FASEB Journal (2017). DOI: 10.1096/fj.201700178R

Related Stories

MicroRNAs identified as novel targets for treating asthma

June 24, 2016
A new study shows that microRNAs, which are small, noncoding RNA molecules that can silence genes, have an important role in inducing asthma. Regulating the function of specific miRNAs identified in the study could represent ...

New research finds novel method for generating airway cells from stem cells

March 30, 2017
Researchers have developed a new approach for growing and studying cells they hope one day will lead to curing lung diseases such as cystic fibrosis through "personalized medicine."

Stem cells show promise – but they also have a darker side

May 25, 2017
Everyone seems to be excited about stem cells. Their excellent promise as a treatment for a range of diseases and injuries mean almost guaranteed coverage for research. While some types of stem cells are already being used ...

Study shows potential of stem cell therapy to repair lung damage

March 24, 2017
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have ...

Proof-of principle study finds imatinib improves symptoms for patients with severe asthma

May 17, 2017
Mast cells, a type of white blood cell, are present in the airways of severe asthmatics even in the face of aggressive treatment, and their presence is associated with key indicators of severe asthma. It has long been thought ...

Recommended for you

New research reveals how the body clock controls inflammation

August 20, 2018
Researchers at RCSI and Trinity College Dublin have revealed insights into how the body clock controls the inflammatory response, which may open up new therapeutic options to treat excess inflammation in conditions such as ...

Strawberries could help reduce harmful inflammation in the colon

August 20, 2018
Inflammatory bowel disease (IBD) is a set of painful conditions that can cause severe diarrhea and fatigue. Treatments can include medications and surgery. But now researchers report that a simple dietary intervention could ...

Newly identified target may help with drug discovery for chronic inflammatory diseases

July 25, 2018
Inflammation is part of the body's natural healing process. But when it becomes chronic, inflammation can lead to cancer, Alzheimer's disease and other conditions. Inflammasomes—protein-based molecular machines—trigger ...

Nicotine mimics may have therapeutic effect on inflammatory diseases

July 12, 2018
Stanford researchers discovered that a receptor that binds to nicotine and to clusters of beta-amyloid molecules is found on certain types of immune cells that can act as suppressors and regulators of the immune system.

Study shows BPA risk factor for inflammatory bowel disease

July 5, 2018
A recent study in a preclinical model of inflammatory bowel disease shows dietary exposure to bisphenol-A, or BPA, found in polycarbonate plastics and epoxy resins, can increase mortality and worsen its symptoms.

Mid- to late-life increases in marker of chronic inflammation tied to dementia

July 2, 2018
Researchers at Johns Hopkins have added to evidence that rising and chronic inflammation as measured by a biomarker in the blood in middle and late age are linked to visible structural changes in the brains of people with ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.